Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AN OPEN LABEL, PROSPECTIVE, POST MARKETING STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF RITUXIMAB WITH GLUCOCORTICOIDS IN ADULT PATIENTS WITH WEGENER'S GRANULOMATOSIS (GRANULOMATOSIS WITH POLYANGIITIS - GPA) OR MICROSCOPIC POLYANGIITIS

Next Previous
X
Search
Trial Profile

AN OPEN LABEL, PROSPECTIVE, POST MARKETING STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF RITUXIMAB WITH GLUCOCORTICOIDS IN ADULT PATIENTS WITH WEGENER'S GRANULOMATOSIS (GRANULOMATOSIS WITH POLYANGIITIS - GPA) OR MICROSCOPIC POLYANGIITIS

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Methylprednisolone; Prednisolone; Prednisone
  • Indications Granulomatosis with polyangiitis; Microscopic polyangiitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Roche

    • Most Recent Events

    • 04 Jul 2022 Status changed from active, no longer recruiting to completed.
    • 06 Jan 2022 Status changed from recruiting to active, no longer recruiting.
    • 06 May 2021 Planned End Date changed from 30 Sep 2021 to 30 Jun 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top